Literature DB >> 6141054

Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol.

C Staiger, F Schlicht, E Walter, U Gundert-Remy, R Hildebrandt, J de Vries, N S Wang, J Harenberg, E Weber.   

Abstract

Sulphinpyrazone decreases the plasma clearance of tolbutamide and S-warfarin and increases the clearance of R-warfarin, theophylline and antipyrine. In order to determine whether sulphinpyrazone is an inducer or inhibitor or both of oxidative drug metabolism, antipyrine and its metabolites as well as 6-beta-hydroxycortisol were measured in urine before, 24 h and after 23 days of chronic administration of sulphinpyrazone (4 X 200 mg/day). During chronic treatment sulphinpyrazone increased the ratio of 6-beta-hydroxycortisol to the 17-hydroxycorticosteroids by 70% (p less than 0.02). The renal clearance of the main oxidative metabolites of antipyrine (4-hydroxyantipyrine, 3-hydroxymethylantipyrine and norantipyrine) were increased after sulphinpyrazone (p less than 0.02). Except for norantipyrine, no change in total excretion of antipyrine and its metabolites occurred after 24 h or after 23 days. It is concluded that sulphinpyrazone induces the enzymes which metabolize antipyrine and cortisol.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6141054     DOI: 10.1007/bf00542523

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Urinary 17-hydroxycorticosteroid determination with p-hydrazinobenzenesulfonic acid-phosphoric acid.

Authors:  A Sanghvi; C Wight; B Parikh; H Desai
Journal:  Am J Clin Pathol       Date:  1973-11       Impact factor: 2.493

2.  Two new metabolites of sulfinpyrazone in the rabbit: a possible cause of the prolonged in vivo effect.

Authors:  A K Pedersen; P Jakobsen
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

3.  Differential effects of enzyme induction on antipyrine metabolite formation.

Authors:  M Danhof; R M Verbeek; C J van Boxtel; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

4.  A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine.

Authors:  B K Park
Journal:  J Steroid Biochem       Date:  1978-10       Impact factor: 4.292

5.  Induction of drug metabolizing enzymes by sulfinpyrazone.

Authors:  E Walter; C Staiger; J de Vries; R Zimmermann; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  A rapid and sensitive method for the determination of phenazone (antipyrine) using gas-liquid-chromatography with nitrogen detection.

Authors:  C Staiger; J de Vries; E Walter
Journal:  J Clin Chem Clin Biochem       Date:  1980-11

7.  Sulfinpyrazone in the prevention of sudden death after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1980-01-31       Impact factor: 91.245

8.  Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man.

Authors:  R A O'Reilly
Journal:  Circulation       Date:  1982-01       Impact factor: 29.690

9.  THE EFFECT OF SULFINPYRAZONE (ANTURAN) ON PLATELET ECONOMY AND BLOOD COAGULATION IN MAN.

Authors:  H A SMYTHE; M A OGRYZLO; E A MURPHY; J F MUSTARD
Journal:  Can Med Assoc J       Date:  1965-04-10       Impact factor: 8.262

10.  Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.

Authors:  M Danhof; E de Groot-van der Vis; D D Breimer
Journal:  Pharmacology       Date:  1979       Impact factor: 2.547

View more
  7 in total

Review 1.  Candidate Proficiency Test Chemicals to Address Industrial Chemical Applicability Domains for in vitro Human Cytochrome P450 Enzyme Induction.

Authors:  Miriam Naomi Jacobs; Barbara Kubickova; Eugene Boshoff
Journal:  Front Toxicol       Date:  2022-06-20

2.  Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol.

Authors:  L A Ferrara; M Mancini; T Marotta; F Pasanisi; M L Fasano
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.

Authors:  P N Shaw; J B Houston; M Rowland; K Hopkins; J F Thiercelin; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

4.  Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.

Authors:  F Schlicht; C Staiger; J de Vries; U Gundert-Remy; R Hildebrandt; J Harenberg; N S Wang; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 5.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

6.  Pharmacokinetics and Reversible Biotransformation of Sulfinpyrazone and Its Metabolites in Rabbits. II. Multiple-Dose Study.

Authors:  B S Kuo; W A Ritschel
Journal:  Pharm Res       Date:  1986-06       Impact factor: 4.200

7.  Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study.

Authors:  Camilla Bernasconi; Olavi Pelkonen; Tommy B Andersson; Judy Strickland; Iwona Wilk-Zasadna; David Asturiol; Thomas Cole; Roman Liska; Andrew Worth; Ursula Müller-Vieira; Lysiane Richert; Christophe Chesne; Sandra Coecke
Journal:  Toxicol In Vitro       Date:  2019-05-31       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.